Rozanolixizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Journal: American journal of therapeutics

Published: January 08, 2026

Body weight distribution of US patients with myasthenia gravis.

Body weight distribution of US patients with myasthenia gravis.

Journal: Journal of medical economics

Published: December 21, 2025

Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.

Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.

Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database.

Journal: Human vaccines & immunotherapeutics

Published: November 13, 2025

Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.

Pharmacological and speech-language pathology management of dysphagia in patients with myasthenia gravis.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: November 10, 2025

Rozanolixizumab as rescue therapy in triple-seronegative refractory generalized myasthenia gravis.

Rozanolixizumab as rescue therapy in triple-seronegative refractory generalized myasthenia gravis.

Journal: Immunological medicine

Published: November 10, 2025

Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.

Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape.

Journal: Expert opinion on emerging drugs

Published: September 23, 2025

Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study.

Blocking the neonatal Fc receptor as a novel approach to prevent cardiac neonatal lupus: a proof-of-concept study.

Journal: Annals of the rheumatic diseases

Published: August 26, 2025

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review.

Management of Myasthenic Crisis and Emerging Roles of Molecularly Targeted Therapies: A Narrative Review.

Journal: Neurology international

Published: August 07, 2025

Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.

Self-administration of rozanolixizumab via manual push and infusion pump methods in patients with generalised myasthenia gravis: a randomised, phase 3, open-label, crossover study.

Journal: Journal of neurology

Published: July 23, 2025

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study.

Journal: Journal of neurology

Published: July 22, 2025

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network.

Journal: Frontiers in immunology

Published: July 21, 2025

Showing 1-12 of 80

Last Updated: 02/24/2026